Bli medlem
Bli medlem

Du är här

2016-10-27

Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED

Reference is made to the prospectus (the "Prospectus") dated 30 September 2016
concerning, inter alia, the subsequent offering (the "Subsequent Offering")
of minimum 1 and maximum 13,333,334 new shares (the "Offer Shares") in
Hofseth BioCare ASA ("HBC" or the "Company", ticker "HBC") and the stock
exchange notice published on 17 October 2016 regarding allocation of Offer
Shares in the Subsequent Offering.

The share capital increase related to the Subsequent Offering has now been
registered with the Norwegian Register of Business Enterprises. The share
capital has been increased with NOK 1,027,494 through issuance of 1,027,494
new shares.

The new share capital is thus NOK 233,499,759 divided by 233,499,759 shares,
each with a par value of NOK 1.

The new shares will be listed and become tradable on Oslo Axess upon duly
registration in the VPS-register on 27 October 2016.

For further information, please contact:
Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that offers high-value ingredients and
finished products for humans and pets. The company is founded on the core
values of sustainability, traceability and optimal utilization of natural
resources. Through an innovative hydrolysis technology, HBC is able to
preserve the quality of salmon oil, proteins and calcium, prepared of fresh
salmon off-cuts. HBC's objective is to contribute to the efficient use of
marine resources and deliver quality products for ingredients and finished
consumer products in the nutrition market.

Hofseth BioCare's headquarters are located in Ålesund, Norway with branches in
Oslo, Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess
list with ticker "HBC". More information about Hofseth BioCare at
www.hofsethbiocare.com and www.facebook.com/hofsethbiocare

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Hofseth Biocare ASA via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.